{"mainPropery":{"diseaseId":8214,"diseaseName":"Lafora disease","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/8214/lafora-disease","synonyms":["Lafora body disorder","Epilepsy progressive myoclonic  2","EPM2","Myoclonic epilepsy of Lafora","MELF"],"synonyms-with-source":[{"name":"Lafora body disorder"},{"name":"Epilepsy progressive myoclonic  2"},{"name":"EPM2"},{"name":"Myoclonic epilepsy of Lafora"},{"name":"MELF"}],"identifiers":[{"identifierType":"OMIM","identifierId":"254780"},{"identifierType":"ORPHANET","identifierId":"501"},{"identifierType":"UMLS","identifierId":"C0751783"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases","source":"Orphanet"}],"organizations":[{"resourceID":413,"resourceName":"Epilepsy Foundation","abbreviation":"","address1":"8301 Professional Place East","address2":"Suite 230","address3":"","address4":"","address5":"","city":"Landover","state":"MD","zip":"20785","country":"United States","phone":"+1-301-459-3700 ","tty":"","tollFree":"800-332-1000 (24/7 Helpline)","fax":"+1-301-577-2684","email":"contactus@efa.org","url":"https://www.epilepsy.com/","freeText":"en Español 1-866-748-8008"},{"resourceID":452,"resourceName":"Chelsea's Hope: Lafora Children Research Fund","address1":"PO Box 1984","address2":"","address3":"","address4":"","address5":"","city":"Danville","state":"CA","zip":"94526","country":"United States","phone":"925-963-7122","tty":"","tollFree":"","fax":"","email":"chelseashope@gmail.com","url":"http://www.chelseashope.org/"}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/254780' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed?term=lafora%20disease%5Btitle%5D%20AND%20hasabstract%5Btext%5D&cmd=DetailsSearch' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Lafora disease. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Lafora+disease%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Lafora disease. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition/lafora-progressive-myoclonus-epilepsy' target='_blank'>MedlinePlus Genetics</a> contains information on Lafora disease. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/C0751783' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='https://rarediseases.org/rare-diseases/progressive-myoclonus-epilepsy/' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=501' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/books/NBK1389/' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:254780' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":2207,"questionText":"What is Lafora disease?","answerText":"<strong>Lafora disease</strong> is an inherited, severe form of <a href=\"http://rarediseases.org/rare-diseases/progressive-myoclonus-epilepsy/\" target=\"_blank\">progressive myoclonus epilepsy</a>. The condition most commonly begins with epileptic seizures in late childhood or adolescence. Other signs and symptoms include difficulty walking, muscle spasms (myoclonus) and <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/000739.htm\" target=\"_blank\">dementia</a>. Affected people also experience rapid cognitive deterioration that begins around the same time as the seizures. The condition is often fatal within 10 years of onset. Most cases are caused by changes (<a href=\"http://www.genome.gov/glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>) in either the <em><a href=\"http://ghr.nlm.nih.gov/gene/EPM2A\" target=\"_blank\">EPM2A</a></em> gene or the <em><a href=\"http://ghr.nlm.nih.gov/gene/NHLRC1\" target=\"_blank\">NHLRC1</a></em> gene and are inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a> manner. Treatment is based on the signs and symptoms present in each person.[9703][9704][9712]","dateModified":"2015-09-29T00:00:00"},"basicQuestions":[{"questionId":9471,"questionText":"What are the signs and symptoms of <span><a name=\"skipnav\"></a>Lafora disease</span>?","answerText":"The signs and symptoms of Lafora disease generally appear during late childhood or adolescence. Prior to the onset of symptoms, affected children appear to have normal development although some may have isolated <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/000980.htm\" target=\"_blank\">febrile</a> or nonfebrile convulsions in infancy or early childhood.[9704]<br />\r\n<br />\r\nThe most common feature of Lafora disease is recurrent <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003200.htm\" target=\"_blank\">seizures</a>. Several different types of seizures have been reported including <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/000695.htm\" target=\"_blank\">generalized tonic-clonic seizures</a>, occipital seizures (which can cause temporary blindness and visual hallucinations) and <a href=\"http://www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/epilepsy/seizures/types/myoclinc-seizures.html\" target=\"_blank\">myoclonic seizures</a>. These seizures are considered \"progressive\" because they generally become worse and more difficult to treat over time.[9703][9704]<br />\r\n<br />\r\nWith the onset of seizures, people with Lafora disease often begin showing signs of cognitive decline. This may include behavioral changes, depression, confusion, ataxia (difficulty controlling muscles), <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/007470.htm\" target=\"_blank\">dysarthria</a>, and eventually, <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/000739.htm\" target=\"_blank\">dementia</a>. By the mid-twenties, most affected people lose the ability to perform the activities of daily living; have continuous <a href=\"http://www.ninds.nih.gov/disorders/myoclonus/detail_myoclonus.htm\" target=\"_blank\">myoclonus</a>; and require tube feeding and comprehensive care.[9703][9704]","dateModified":"2015-09-27T20:51:00","resourceClassificationName":"Symptoms","references":[{"referenceId":9703,"authors":"","articleTitle":"Lafora progressive myoclonus epilepsy","bookWebsiteJournalTitle":"Genetics Home Reference","date":"July 2009","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/condition/lafora-progressive-myoclonus-epilepsy","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9704,"authors":"Anna C Jansen, MD, PhD and Eva Andermann, MD, PhD, FCCMG","articleTitle":"Progressive Myoclonus Epilepsy, Lafora Type","bookWebsiteJournalTitle":"GeneReviews","date":"January 2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1389/#lafora.Clinical_Description","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":9476,"questionText":"What causes Lafora disease?","answerText":"Most cases of Lafora disease are caused by changes (<a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>) in either the <em><a href=\"http://ghr.nlm.nih.gov/gene/EPM2A\" target=\"_blank\">EPM2A</a></em> gene or the <em><a href=\"http://ghr.nlm.nih.gov/gene/NHLRC1\" target=\"_blank\">NHLRC1</a></em> gene. These genes encode proteins that play a critical role in the survival of nerve cells (neurons) in the brain. Although the proteins are thought to have many functions in the body, one important role is to help regulate the production of a complex sugar called glycogen (an important source of stored energy in the body). Mutations in the <em>EPM2A</em> gene or the <em>NHLRC1</em> gene interfere with the production of functional proteins, leading to the formation of Lafora bodies (clumps of abnormal glycogen that cannot be broken down and used for fuel) within cells. A build up of Lafora bodies appears to be especially toxic to the cells of the nervous system and leads to the signs and symptoms of Lafora disease.[9703]","dateModified":"2015-09-28T14:46:00","resourceClassificationName":"Cause","references":[{"referenceId":9703,"authors":"","articleTitle":"Lafora progressive myoclonus epilepsy","bookWebsiteJournalTitle":"Genetics Home Reference","date":"July 2009","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/condition/lafora-progressive-myoclonus-epilepsy","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":9478,"questionText":"Is <span id=\"ctl00_MainContent_LabelDiseaseName\">Lafora disease</span> inherited?","answerText":"Lafora disease is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a> manner.[9704] This means that to be affected, a person must have a <a href=\"http://www.genome.gov/glossary/index.cfm?id=134\" target=\"_blank\">mutation</a> in both copies of the responsible <a href=\"http://www.genome.gov/glossary/index.cfm?id=70\" target=\"_blank\">gene</a> in each cell. The parents of an affected person usually each carry one mutated copy of the gene and are referred to as carriers. Carriers typically do not show signs or symptoms of the condition. When two carriers of an autosomal recessive condition have children, each child has a 25% (1 in 4) risk to have the condition, a 50% (1 in 2) risk to be a carrier like each of the parents, and a 25% chance to not have the condition <em>and</em> not be a carrier.","dateModified":"2015-09-28T19:55:00","resourceClassificationName":"Inheritance","references":[{"referenceId":9704,"authors":"Anna C Jansen, MD, PhD and Eva Andermann, MD, PhD, FCCMG","articleTitle":"Progressive Myoclonus Epilepsy, Lafora Type","bookWebsiteJournalTitle":"GeneReviews","date":"January 2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1389/#lafora.Clinical_Description","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":9479,"questionText":"How is Lafora disease diagnosed?","answerText":"A diagnosis of Lafora disease is often suspected based on the presence of characteristic <a href=\"https://rarediseases.info.nih.gov/gard/8214/lafora-disease/resources/9\" target=\"_blank\">signs and symptoms</a>. Additional testing can then be ordered to confirm the diagnosis and rule out other conditions that may cause similar features. For example, a <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003840.htm\" target=\"_blank\">skin biopsy</a> may be performed to detect \"Lafora bodies\" (clumps of abnormal glycogen that cannot be broken down and used for fuel) which are found in most people with the condition. Genetic testing for changes (<a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>) in either the <em><a href=\"http://ghr.nlm.nih.gov/gene/EPM2A\" target=\"_blank\">EPM2A</a></em> gene or the <em><a href=\"http://ghr.nlm.nih.gov/gene/NHLRC1\" target=\"_blank\">NHLRC1</a></em> gene may be used to confirm the diagnosis in some cases. An <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003931.htm\" target=\"_blank\">EEG</a> and an <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003791.htm\" target=\"_blank\">MRI of the brain</a> are generally recommended in all people with recurrent seizures and are useful in investigating other conditions in the differential diagnosis.[9704][9712]<br />\r\n<br />\r\n<a href=\"http://www.ncbi.nlm.nih.gov/books/NBK1389/#lafora.Diagnosis\" target=\"_blank\">GeneReview's</a> Web site offers more specific information regarding the diagnosis of Lafora disease. Please click on the link to access this resource. <br />","dateModified":"2015-09-28T20:33:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":9704,"authors":"Anna C Jansen, MD, PhD and Eva Andermann, MD, PhD, FCCMG","articleTitle":"Progressive Myoclonus Epilepsy, Lafora Type","bookWebsiteJournalTitle":"GeneReviews","date":"January 2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1389/#lafora.Clinical_Description","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9712,"authors":"Monaghan TS, Delanty N","articleTitle":"Lafora disease: epidemiology, pathophysiology and management","bookWebsiteJournalTitle":"CNS Drugs","date":"July 2010","volume":"24(7)","pages":"549-561","url":"","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":9480,"questionText":"How might Lafora disease be treated?","answerText":"Unfortunately, there is currently no cure or way to slow the progression of Lafora disease. Treatment is based on the signs and symptoms present in each person. For example, certain medications may be recommended to manage&nbsp;<a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/000695.htm\" target=\"_blank\">generalized seizures</a>. In the advanced stages of the condition, a <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/002937.htm\" target=\"_blank\">gastrostomy tube</a> may be placed for feeding. Drugs that are known to worsen <a href=\"http://www.ninds.nih.gov/disorders/myoclonus/detail_myoclonus.htm\" target=\"_blank\">myoclonus</a> (i.e. <a href=\"https://www.nlm.nih.gov/medlineplus/druginfo/meds/a682022.html\" target=\"_blank\">phenytoin</a>) should be avoided.[9704][9712]<br />\r\n<br />","dateModified":"2015-09-28T21:05:00","resourceClassificationName":"Treatment","references":[{"referenceId":9704,"authors":"Anna C Jansen, MD, PhD and Eva Andermann, MD, PhD, FCCMG","articleTitle":"Progressive Myoclonus Epilepsy, Lafora Type","bookWebsiteJournalTitle":"GeneReviews","date":"January 2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1389/#lafora.Clinical_Description","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9712,"authors":"Monaghan TS, Delanty N","articleTitle":"Lafora disease: epidemiology, pathophysiology and management","bookWebsiteJournalTitle":"CNS Drugs","date":"July 2010","volume":"24(7)","pages":"549-561","url":"","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":9481,"questionText":"What is the long-term outlook for people with Lafora disease?","answerText":"The long-term outlook (prognosis) for people with Lafora disease is unfortunately poor. There is currently no cure for the condition and it is considered progressive (symptoms worsen over time). By the mid-twenties, most affected people lose the ability to perform the activities of daily living; have continuous <a href=\"http://www.ninds.nih.gov/disorders/myoclonus/detail_myoclonus.htm\" target=\"_blank\">myoclonus</a>; and require tube feeding and comprehensive care. On average, affected people survive approximately 10 years after the onset of symptoms.[9703][9704]","dateModified":"2015-09-28T21:27:00","resourceClassificationName":"Prognosis","references":[{"referenceId":9703,"authors":"","articleTitle":"Lafora progressive myoclonus epilepsy","bookWebsiteJournalTitle":"Genetics Home Reference","date":"July 2009","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/condition/lafora-progressive-myoclonus-epilepsy","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9704,"authors":"Anna C Jansen, MD, PhD and Eva Andermann, MD, PhD, FCCMG","articleTitle":"Progressive Myoclonus Epilepsy, Lafora Type","bookWebsiteJournalTitle":"GeneReviews","date":"January 2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1389/#lafora.Clinical_Description","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":7140,"relatedDiseaseName":"Progressive myoclonic epilepsy","relation":"Parent","isRare":true,"hasGardPage":true}],"gardCases":[{"caseId":39801,"abbreviatedInquiry":"Have there been any advances that suggest anything can slow the progression of disease? Why is there so little information on this disease? Are there any other resources that show up to date information?","caseQuestions":[{"questionId":6910,"questionText":"Have there been any advances that suggest anything can slow the progression of Lafora&nbsp;disease?","answerText":"There are currently no treatments available to slow the progression of Lafora disease. However, there is ongoing research regarding potential future treatments. For example, there has been research on mice with Lafora disease that were bred with mice that have a <a href=\"http://www.genome.gov/12514551\" target=\"_blank\">knockout</a> of the PTG gene (an inactivated copy of the gene). The PTG gene provides instructions for one of the enzymes that modify glycogen synthase activity. If it is not functional, or &ldquo;knocked out,&rdquo; no Lafora disease develops. This research may show that the disease&nbsp;could be prevented by indirectly altering glycogen synthase function.[6030] An article with more information about this research can be viewed by <a href=\"http://www.checkorphan.org/grid/news/research/high-hopes-for-future-treatment-of-lafora-disease?q=lafora\" target=\"_blank\">clicking here</a>.","dateModified":"2015-09-29T00:00:00","references":[{"referenceId":6030,"authors":"Kathrin Schemmer","articleTitle":"High Hopes for Future Treatment of Lafora Disease","bookWebsiteJournalTitle":"CheckOrphan","date":"May 27, 2011","url":"http://www.checkorphan.org/grid/news/research/high-hopes-for-future-treatment-of-lafora-disease?q=lafora","dateAccessed":"2013-06-10T00:00:00"}]},{"questionId":6908,"questionText":"Why is there little information about Lafora disease available?","answerText":"Lafora disease affects a small number of people compared to the general population and is considered rare in many parts of the world.[6033] Unfortunately, the field of rare diseases as a whole suffers from a shortage of medical and scientific knowledge, largely due to lack of awareness and funding sources. Until recently there was no real research or public health policy concerning issues related to the field. Those affected by these diseases face similar difficulties in their quest for relevant information and proper direction towards qualified professionals.[6033] On a positive note, there are now several organizations aiming to raise awareness of rare diseases as well as funding programs to support rare disease research and potential therapies.","dateModified":"2015-09-29T00:00:00","references":[{"referenceId":6033,"authors":"","articleTitle":"About Rare Diseases","bookWebsiteJournalTitle":"Orphanet","date":"October 25, 2012","url":"http://www.orpha.net/consor/cgi-bin/Education_AboutRareDiseases.php?lng=EN","dateAccessed":"2013-06-11T00:00:00"}]},{"questionId":6909,"questionText":"Where can I find up-to-date information about&nbsp;Lafora disease?","answerText":"You can find relevant articles on Lafora disease through <a href=\"http://www.ncbi.nlm.nih.gov/pubmed\" target=\"_blank\">PubMed</a>, a searchable database of biomedical journal articles. Although not all of the articles are available for free online, most articles listed in PubMed have a summary available. To obtain the full article, contact a medical/university library or your local library for interlibrary loan. You can also order articles online through the publisher&rsquo;s Web site. Using \"Lafora disease\" as your search term should help you locate articles. <a href=\"http://www.ncbi.nlm.nih.gov/pubmed?term=lafora%5BTitle%5D%20AND%20disease%5BTitle%5D&amp;cmd=DetailsSearch\" target=\"_blank\">Click here to view a search</a>.<br />\r\n<br />\r\nThe National Library of Medicine (NLM) Web site has a page for locating libraries in your area that can provide direct access to these journals (print or online). The Web page also describes how you can get these articles through interlibrary loan and Loansome Doc (an NLM document-ordering service). You can access this page at the following link <a href=\"http://nnlm.gov/members/\" target=\"_blank\">http://nnlm.gov/members/</a>. You can also contact the NLM toll-free at 888-346-3656 to locate libraries in your area.","dateModified":"2015-09-29T00:00:00","references":[]}]},{"caseId":34713,"abbreviatedInquiry":"Is a ketogenic diet known to help individuals with Lafora disease?","caseQuestions":[{"questionId":6129,"questionText":"Is a ketogenic diet known to help&nbsp;people with Lafora disease (LD)?","answerText":"The impact of a long-term ketogenic diet was studied in five people with Lafora disease. Although the diet was well-tolerated by patients, it did not stop disease progression or improve symptoms. However, given the small study population, the researchers could not exclude the possibility that a ketogenic diet has the potential to slow down the disease progression. Larger studies are needed to evaluate the impact of a ketogenic diet in treating patients with Lafora disease.[5161]","dateModified":"2015-09-29T00:00:00","references":[{"referenceId":5161,"authors":"Cardinali S, Canafoglia L, Bertoli S, Franceschetti S, Lanzi G, Tagliabue A, Veggiotti P","articleTitle":"A pilot study of a ketogenic diet in patients with Lafora body disease","bookWebsiteJournalTitle":"Epilepsy Res","date":"2006","volume":"69(2)","pages":"129-34","url":"http://www.ncbi.nlm.nih.gov/pubmed/16504479","dateAccessed":"2012-04-12T00:00:00"}]}]},{"caseId":24111,"abbreviatedInquiry":"Can an adult get Lafora disease?","caseQuestions":[{"questionId":2207,"questionText":"What is Lafora disease?","answerText":"<strong>Lafora disease</strong> is an inherited, severe form of <a href=\"http://rarediseases.org/rare-diseases/progressive-myoclonus-epilepsy/\" target=\"_blank\">progressive myoclonus epilepsy</a>. The condition most commonly begins with epileptic seizures in late childhood or adolescence. Other signs and symptoms include difficulty walking, muscle spasms (myoclonus) and <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/000739.htm\" target=\"_blank\">dementia</a>. Affected people also experience rapid cognitive deterioration that begins around the same time as the seizures. The condition is often fatal within 10 years of onset. Most cases are caused by changes (<a href=\"http://www.genome.gov/glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>) in either the <em><a href=\"http://ghr.nlm.nih.gov/gene/EPM2A\" target=\"_blank\">EPM2A</a></em> gene or the <em><a href=\"http://ghr.nlm.nih.gov/gene/NHLRC1\" target=\"_blank\">NHLRC1</a></em> gene and are inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a> manner. Treatment is based on the signs and symptoms present in each person.[9703][9704][9712]","dateModified":"2015-09-29T00:00:00","references":[{"referenceId":9703,"authors":"","articleTitle":"Lafora progressive myoclonus epilepsy","bookWebsiteJournalTitle":"Genetics Home Reference","date":"July 2009","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/condition/lafora-progressive-myoclonus-epilepsy","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9704,"authors":"Anna C Jansen, MD, PhD and Eva Andermann, MD, PhD, FCCMG","articleTitle":"Progressive Myoclonus Epilepsy, Lafora Type","bookWebsiteJournalTitle":"GeneReviews","date":"January 2015","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1389/#lafora.Clinical_Description","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9712,"authors":"Monaghan TS, Delanty N","articleTitle":"Lafora disease: epidemiology, pathophysiology and management","bookWebsiteJournalTitle":"CNS Drugs","date":"July 2010","volume":"24(7)","pages":"549-561","url":"","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":2208,"questionText":"Can an adult get Lafora disease?","answerText":"Lafora disease typically begins between ages 12 and 17 years, after a period of apparently normal development. However, there are reports of later onset forms of the condition. In these cases,the affected person often begins showing signs and symptoms of Lafora disease between ages 21 and 28. Some studies suggest that later onset cases of Lafora disease may be associated with a slower disease progression.[1359][9718]","dateModified":"2015-09-29T00:00:00","references":[{"referenceId":1359,"authors":"Lhi H, Turnbull J, Zhao XC, Pullenayegum S, Ianzano L, Yahyaoui M, Mikati MA, Quinn NP, Francheschetti S, Zara F, Minassian BA","articleTitle":"","bookWebsiteJournalTitle":"Neurology","date":"2007","url":"http://www.ncbi.nlm.nih.gov/pubmed/17389303","dateAccessed":"2009-07-06T00:00:00"},{"referenceId":9718,"authors":"Jara-Prado A, Ochoa A, Alonso ME, Lima Villeda GA, Fernández-Valverde F, Ruano-Calderón L, Vargas-Cañas S, Durón RM, Delgado-Escueta AV, Martínez-Juárez IE","articleTitle":"Late onset Lafora disease and novel EPM2A mutations: breaking paradigms","bookWebsiteJournalTitle":"Epilepsy Res. 2014 Nov;108(9):1501-10","date":"November 2014","volume":"108(9)","pages":"1501-1510","url":"","authors2":"","placeOfPublication":"","publisher":""}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":263,"phenoTypeName":"Lafora bodies","frequencyText":"Obligate","percentRanges":"100%"},{"phenoTypeId":8720,"phenoTypeName":"Ataxia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":9380,"phenoTypeName":"Confusion","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":6020,"phenoTypeName":"Dementia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":6011,"phenoTypeName":"Depressivity","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8703,"phenoTypeName":"Dysarthria","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":6009,"phenoTypeName":"Emotional lability","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":3821,"phenoTypeName":"Erratic myoclonus","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13747,"phenoTypeName":"Generalized myoclonic seizure","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":9403,"phenoTypeName":"Giant somatosensory evoked potentials","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11409,"phenoTypeName":"Headache","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":14306,"phenoTypeName":"Hypsarrhythmia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":14222,"phenoTypeName":"Inability to walk","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13940,"phenoTypeName":"Nasogastric tube feeding","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13732,"phenoTypeName":"Recurrent aspiration pneumonia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8711,"phenoTypeName":"Spasticity","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13751,"phenoTypeName":"Status epilepticus","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11435,"phenoTypeName":"Visual hallucinations","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11204,"phenoTypeName":"Atonic seizure","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13649,"phenoTypeName":"Atypical absence seizure","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13667,"phenoTypeName":"Bilateral tonic-clonic seizure with focal onset","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":2466,"phenoTypeName":"Brain atrophy","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5162,"phenoTypeName":"Focal impaired awareness seizure","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":10615,"phenoTypeName":"Focal sensory seizure with visual features","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5685,"phenoTypeName":"Hepatic failure","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":913,"phenoTypeName":"Severe photosensitivity","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":11439,"phenoTypeName":"Sleep disturbance","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":7186,"phenoTypeName":"Vegetative state","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13858,"phenoTypeName":"Apraxia","percentRanges":"-"},{"phenoTypeId":4,"phenoTypeName":"Autosomal recessive inheritance","percentRanges":"-"},{"phenoTypeId":8275,"phenoTypeName":"Cutaneous photosensitivity","percentRanges":"-"},{"phenoTypeId":9379,"phenoTypeName":"Gait disturbance","percentRanges":"-"},{"phenoTypeId":13746,"phenoTypeName":"Generalized non-motor (absence) seizure","percentRanges":"-"},{"phenoTypeId":10639,"phenoTypeName":"Myoclonus","percentRanges":"-"},{"phenoTypeId":11425,"phenoTypeName":"Progressive neurologic deterioration","percentRanges":"-"},{"phenoTypeId":6006,"phenoTypeName":"Psychosis","percentRanges":"-"},{"phenoTypeId":5257,"phenoTypeName":"Rapidly progressive","percentRanges":"-"},{"phenoTypeId":9162,"phenoTypeName":"Visual loss","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"Lafora_disease"}